×
About 50 results

ALLMedicine™ Angioimmunoblastic Lymphoma Center

Research & Reviews  18 results

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05313243

Oct 12th, 2022 - CD30- Positive Peripheral T cell (PTCL) and Cutaneous T cell Lymphomas (CTCL): T-cell Non-Hodgkin Lymphoma (NHL) includes a clinically heterogeneous group of mature T-cell lymphomas accounting for 10-12% of all NHL. Peripheral T- cell Lymphoma (PT...

Non-Hodgkin Lymphoma (NHL)
https://emedicine.medscape.com/article/203399-overview

Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...

Non-Hodgkin Lymphoma (NHL)
http://emedicine.medscape.com/article/203399-overview

Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...

Non-Hodgkin Lymphoma (NHL)
https://emedicine.medscape.com/article/203399-

Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...

Non-Hodgkin Lymphoma (NHL)
https://emedicine.medscape.com/article/203399-print

Aug 3rd, 2021 - Practice Essentials Non-Hodgkin lymphomas (NHLs) are tumors originating from lymphoid tissues, mainly of lymph nodes. These tumors may result from chromosomal translocations, infections, environmental factors, immunodeficiency states, and chronic ...

see more →

Clinicaltrials.gov  2 results

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05313243

Oct 12th, 2022 - CD30- Positive Peripheral T cell (PTCL) and Cutaneous T cell Lymphomas (CTCL): T-cell Non-Hodgkin Lymphoma (NHL) includes a clinically heterogeneous group of mature T-cell lymphomas accounting for 10-12% of all NHL. Peripheral T- cell Lymphoma (PT...

Allo-hNHL (FluBuCy)
https://clinicaltrials.gov/ct2/show/NCT00785330

Jan 13th, 2020 - Patients in the age of 18 to 65 years with a high- risk relapse of a histology proven aggressive Non-Hodgkin's-lymphoma are eligible for the trial. Aggressive Non-Hodgkin's lymphoma within this study is defined as: B-NHL: follicular lymphoma grade...

see more →